PhRMA Defends 30-Month ANDA Stay In McCain/Schumer Position Paper
This article was originally published in The Tan Sheet
Executive Summary
The brand vs. generic industry positioning surrounding proposed Hatch/Waxman process reforms includes conflicting arguments over the potential for standard intellectual property procedures to protect pharmaceutical companies from patent infringement.